

Supplementary Material

Supplementary Figure 1. Study design. EOT=end of treatment; IV=intravenous.



Supplementary Table 1. All Treatment Regimens for Patients Receiving Standard of Care (Safety Population)

Regimen	SOC, no./No. (%)	Baseline Pathogen(s) in Bone
Vancomycin IV x 29–30 d (D1–29 or D1–30)	3/10 (30)	<i>Corynebacterium striatum</i> (n=1); <i>Staphylococcus epidermidis</i> (n=1); MSSA + <i>Enterococcus faecalis</i> (n=1) ^a
Vancomycin IV x 5 d (D1–5); linezolid IV x 25 d (D5–29)	1/10 (10)	MSSA + <i>Staphylococcus epidermidis</i> + <i>Streptococcus agalactiae</i>
Vancomycin IV x 6 d (D1–6); linezolid IV x 24 d (D6–29) ^b	1/10 (10)	MRSA + <i>Klebsiella pneumoniae</i> + <i>Proteus mirabilis</i>
Vancomycin IV x 8 d (D1–8); levofloxacin IV x 22 d (D8–29)	1/10 (10)	MSSA
Vancomycin IV x 16 d (D1–16); levofloxacin IV x 15 d (D15–29)	1/10 (10)	MSSA
Vancomycin IV x 7 d (D1–7); linezolid IV plus cefotaxime IV x 43 d (D7–49) ^c	1/10 (10)	MSSA + <i>Pseudomonas aeruginosa</i> + <i>Raoultella planticola</i> + <i>Serratia marcescens</i>
Excluded from mITT population due to only Gram-negative pathogens in bone		
Vancomycin IV x 16 d (D1–16); amikacin IV x 13 d (D8–20) ^{d,e}	1/10 (10)	<i>Klebsiella pneumoniae</i> + <i>Proteus mirabilis</i>

Vancomycin IV x 5 d (D1–5); IV 1/10 (10) *Enterobacter cloacae complex* +
ceftriaxone x 25 d (D4–29)^d *Escherichia coli* + *Klebsiella oxytoca*

IV=intravenous; all regimens were q12h. d=days; D=Study Day. MRSA=methicillin-resistant *Staphylococcus aureus*; MSSA=methicillin-susceptible *S. aureus*; SOC=standard of care; mITT=modified intent-to-treat

^aIndeterminate at 6 months and 1 year due to loss to followup. ^bReceived adjunctive aztreonam.

^cClinical failure at day 42 due to receipt of antibiotics > 6 weeks. ^dDiscontinued study drug per protocol when baseline bone culture results showed only gram-negative pathogens; given appropriate gram-negative antibiotic. ^eWithdrew from study on day 20 (withdrew consent)

Supplementary Table 2. Clinical Cure at Day 42 by Baseline Pathogen (CE Population)

Pathogen, n/N (%)^a	Dalbavancin	Standard of Care
Gram-positive aerobes		
<i>Staphylococcus aureus</i>	41/42 (97.6) ^b	5/6 (83.3) ^c
MRSA	4/4 (100)	1/1 (100)
MSSA	37/38 (97.4) ^b	4/5 (80.0) ^c
Coagulase-negative staphylococci	12/14 (85.7) ^d	2/2 (100) ^e
<i>Enterococcus faecalis</i>	7/7 (100)	1/1 (100)
<i>Enterococcus faecium</i>	1/1 (100)	0
<i>Streptococcus agalactiae</i>	1/1 (100)	1/1 (100)
<i>Streptococcus dysgalactiae</i>	1/1 (100)	0
<i>Streptococcus pyogenes</i>	1/1 (100)	0
<i>Corynebacterium striatum</i>	2/2 (100)	1/1 (100)
<i>Aerococcus viridans</i>	1/1 (100)	0
<i>Globicatella</i> spp	1/1 (100)	0
<i>Micrococcus luteus</i>	1/1 (100)	0
Gram-positive anaerobes		
<i>Peptoniphilus harei</i>	2/2 (100)	0
<i>Anaerococcus prevotii</i>	1/1 (100)	0
<i>Fingoldia magna</i>	1/1 (100)	0
<i>Peptostreptococcus anaerobius</i>	1/1 (100)	0
Gram-negative aerobes		
<i>Escherichia coli</i>	3/3 (100)	0

<i>Klebsiella pneumoniae</i>	2/2 (100)	1/1 (100)
<i>Enterobacter cloacae complex</i>	2/2 (100)	0
<i>Morganella morganii</i>	2/2 (100)	0
<i>Pseudomonas aeruginosa</i>	2/2 (100)	0/1 (0) ^c
<i>Proteus mirabilis</i>	1/1 (100)	1/1 (100)
<i>Raoultella planticola</i>	1/1 (100)	0/1 (0) ^c
<i>Acinetobacter calcoaceticus</i>	1/1 (100)	0
<i>Escherichia hermannii</i>	1/1 (100)	0
<i>Pluralibacter gergoviae</i>	1/1 (100)	0
<i>Serratia marcescens</i>	0	0/1 (0) ^c

Gram-negative anaerobes

<i>Bacteroides fragilis</i>	2/2 (100)	0
<i>Bacteroides thetaiotaomicron</i>	1/1 (100)	0
<i>Bacteroides vulgatus</i>	1/1 (100)	0
<i>Porphyromonas asaccharolytica</i>	2/2 (100)	0
<i>Prevotella melaninogenica</i>	2/2 (100)	0
<i>Prevotella disiens</i>	1/1 (100)	0
<i>Prevotella intermedia</i>	1/1 (100)	0
<i>Prevotella spp</i>	1/1 (100)	0

CE=clinically evaluable; MRSA=methicillin-resistant *Staphylococcus aureus*; MSSA=methicillin-susceptible *Staphylococcus aureus*; SOC=standard of care.

^aCategories are not mutually exclusive.

^bOne patient was indeterminate due to loss to followup after day 8 visit.

^cOne patient was a failure due to requirement of > 6 weeks of SOC antibiotics.

^dTwo patients were indeterminate due to loss to followup after day 8 visit. Coagulase-negative staphylococci [n/N (%)]: *S. epidermidis*, 6/6 (100); *S. haemolyticus*, 3/4 (75); *S. hominis*, 1/2 (50); *S. pasteurii*, 1/1 (100); *S. simulans*, 1/1 (100).

^eCoagulase-negative staphylococci [n/N (%)]: *S. epidermidis*, 2/2 (100).

Supplementary Table 3. Baseline Pathogens in Patients with Mixed Infection, with Gram-Positive and Gram-Negative Aerobic Organism in Bone (Safety Population)

Baseline Pathogen, by Patient	Site of Osteomyelitis	Clinical Response at Day 42
Dalbavancin Group		
1. MSSA, <i>Escherichia coli</i> (plus anaerobes <i>Bacteroides fragilis</i> , <i>Peptoniphilus harei</i>)	Hand	Cure
2. <i>Enterococcus faecalis</i> , <i>Enterobacter cloacae</i> complex (plus anaerobe <i>Prevotella intermedia</i>)	Tibia	Cure
3. MSSA, <i>Enterococcus faecalis</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> (plus anaerobes <i>Bacteroides fragilis</i> , <i>Bacteroides vulgatus</i>)	Diabetic foot	Cure
4. <i>Staphylococcus haemolyticus</i> , <i>Streptococcus dysgalactiae</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i>	Foot (not diabetic)	Cure
5. MSSA, <i>Morganella morganii</i> , <i>Proteus mirabilis</i> (plus anaerobes <i>Bacteroides thetaiotaomicron</i> , <i>Porphyromonas asaccharolytica</i>)	Foot (not diabetic)	Cure
6. MSSA, <i>Morganella morganii</i> (plus anaerobe <i>Fingoldia magna</i>)	Foot (not diabetic)	Cure
7. <i>Staphylococcus epidermidis</i> , <i>Enterococcus faecalis</i> , <i>Escherichia hermannii</i> , <i>Pluralibacter gergoviae</i> , <i>Raoultella planticola</i>	Diabetic Foot	Cure

8. MSSA, <i>Staphylococcus haemolyticus</i> , <i>Acinetobacter calcoaceticus</i>	Patella	Cure
9. <i>Staphylococcus simulans</i> , <i>Pseudomonas aeruginosa</i>	Tibia	Cure
10. MSSA, <i>Pseudomonas aeruginosa</i>	Femur	Cure
11. MSSA, <i>Enterobacter cloacae</i> complex (plus anaerobes <i>Peptoniphilus harei</i> , <i>Prevotella disiens</i>)	Foot (not diabetic)	Cure

SOC Group

- | | | |
|--|-------|---------|
| 1. MSSA, <i>Pseudomonas aeruginosa</i> , <i>Raoultella planticola</i> , <i>Serratia marcescens</i> | Tibia | Failure |
| 2. MRSA, <i>Klebsiella pneumoniae</i> , <i>Proteus mirabilis</i> | Femur | Cure |

MRSA=methicillin-resistant *Staphylococcus aureus*; MSSA= methicillin-susceptible

Staphylococcus aureus; SOC=standard of care.

Supplementary Figure 2. CRP levels in the mITT population in the A) dalbavancin group and B) SOC group. CRP=C-reactive protein; mITT=modified intent-to-treat; SOC=standard of care.

